Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA(2)LEN
| Autor: | Cruz, A. A., Popov, T., Pawankar, R., Annesi-Maesano, Isabella, Fokkens, W., Kemp, J., Ohta, K., Price, D., Bousquet, J., Renseigné, Non |
|---|---|
| Přispěvatelé: | Laboratoire d'Informatique de Paris-Nord (LIPN), Université Sorbonne Paris Cité (USPC)-Institut Galilée-Université Paris 13 (UP13)-Centre National de la Recherche Scientifique (CNRS), Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Dermatology, Medical School-Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Merlin Circuit Technology LTD, AA Cruz, T Popov, R Pawankar, Annesi-Maesano I, Fokkens W, Kemp J, K Ohta, Prix D, Bousquet J, scientifique Comité d'initiative ARIA ., Université Paris 13 (UP13)-Institut Galilée-Université Sorbonne Paris Cité (USPC)-Centre National de la Recherche Scientifique (CNRS) |
| Jazyk: | angličtina |
| Rok vydání: | 2007 |
| Předmět: |
medicine.medical_specialty
Allergy Rhinitis Allergic Perennial MESH: Asthma MESH: Immunotherapy Immunology MEDLINE Atopy 03 medical and health sciences 0302 clinical medicine Risk Factors MESH: Risk Factors Internal medicine Immunopathology Prevalence medicine Humans Immunology and Allergy 030212 general & internal medicine Risk factor MESH: Prevalence Asthma MESH: Humans MESH: Rhinitis Allergic Perennial business.industry Respiratory disease Rhinitis Allergic Seasonal MESH: Rhinitis Allergic Seasonal medicine.disease 3. Good health respiratory tract diseases Increased risk 030228 respiratory system [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie Immunotherapy business |
| Zdroj: | Allergy Allergy, Wiley, 2007, 62 Suppl 84, pp.1-41. ⟨10.1111/j.1398-9995.2007.01551.x⟩ Allergy, 2007, 62 Suppl 84, pp.1-41. ⟨10.1111/j.1398-9995.2007.01551.x⟩ |
| ISSN: | 0105-4538 1398-9995 |
| DOI: | 10.1111/j.1398-9995.2007.01551.x |
| Popis: | International audience; This update aimed to review the new evidence available to support or refute prior Allergic Rhinitis and its Impact on Asthma (ARIA) statements. A Medline search of publications between 2000 and 2005 was conducted, with articles selected by experts. New evidence supports previous ARIA statements, such as: (i) allergic rhinitis (AR) is a risk factor for asthma; (ii) patients with persistent rhinitis should be evaluated for asthma; (iii) most patients with asthma have rhinitis; (iv) a combined strategy should be used to treat the airways and (v) in low- to middle-income countries, a different strategy may be needed. The increased risk of asthma has also been found among sufferers from non-AR. Recent reports show AR is a global problem. Many studies demonstrated parallel increasing prevalence of asthma and rhinitis, but in regions of highest prevalence, it may be reaching a plateau. Factors associated with a reduced risk of asthma and AR have been identified, confirming previous findings of protection related to exposure to infections. Treatment of rhinitis with intranasal glucocorticosteroids, antihistamines, leukotriene antagonists or immunotherapy may reduce morbidity because of asthma. To take advantage of the paradigm of unified airways, there is a need to rationalize diagnosis and treatment to optimize management. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text